Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us
Source
bskyPhenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Usdoi.orgYou might also wanna read
GLP-1 Receptor Agonists Linked to Small Risk of Smell and Taste Disturbances in Type 2 Diabetes
A study published in JAMA Otolaryngology-Head & Neck Surgery found that GLP-1 receptor agonists (RAs) used for type 2 diabetes are associate
mdsc.pe·3d ago
Study Finds GLP-1 Drugs Associated with 58% Lower Mortality in Colon Cancer Patients
A study analyzing over 6,800 colon cancer patients across University of California Health sites found that patients taking GLP-1 medications
Impact of GLP-1s on Life Insurance and Insights from a Health Tech Event
The article discusses the impact of GLP-1s on life insurance and shares insights from a health tech event in Amsterdam. It also highlights t
glp1digest.com·11mo ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption
This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica
bmj.com·15d ago
Conflicts of interest threaten integrity of GLP-1 therapy guidance, experts warn
This article discusses the risks of conflicts of interest in clinical guidance for GLP-1 receptor agonists (like Ozempic, Wegovy) used for o
bit.ly·15d ago
Study: Stopping GLP-1 Drugs Increases Heart Attack and Stroke Risk
New research published in BMJ Medicine reveals that stopping GLP-1 drugs (originally for diabetes, now popular for weight loss) leads to a r
nautil.us·3mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.